Yes, Vascepa and Statin reduced hsCRP by 22% versus statin alone in the ANCHOR trial.
Okay, hsCRP, this was the big research find that led to the successful Crestor (rosuvastatin) JUPITER trial. From the video here: www.youtube.com/watch
Brigham and Women's Hospital researchers found that patients with increased levels of hsCRP (high sensitivity C-reactive protein) are at high risk of heart disease even if their (NYSE:LDL) cholesterol is low.
hsCRP is a more specific indicator of cardiovascular inflammation compared to the general CRP which is more a marker of systemic inflammation which could be due to a variety of causes, such as infection.
Read about hsCRP at the Cleveland Clinic: my.clevelandclinic.org/heart/services/tests/labtests/testscad.aspx
Ultra Sensitive C-Reactive Protein Blood (HS-CRP)
- C-reactive protein measures an inflammatory response in the body and has been shown to play a role in atherosclerosis and blood clot formation.
- Patients should ask their doctor specifically about hs-CRP, as this test helps determine heart disease risk. Elevated HS-CRP is related to increased risk for heart attack, restenosis of coronary arteries after angioplasty, stroke, and peripheral vascular disease (NYSE:PVD).
- While elevated cholesterol, LDL and triglycerides and low HDL are all independent risk factors for heart disease and cholesterol build-up, HS-CRP provides additional information about inflammation in the arteries - something not determined by lipid testing alone.
Since Vascepa (EPA or Eicosapentaenoic Acid) acts to counter the over-active inflammation pathway that is driven by an over-abundance of Arachidonic Acid in our bodies (mainly due to our diets of Omega 6 fatty acids), Vascepa should be expected to lower overall systemic inflammation (NYSE:CRP) as well as the more specific cardio-inflammation marker (hsCRP). This bodes well for seeing actual benefits to patient's cardiovascular health.
Disclosure: I am long AMRN.